The FDA has approved GSK's gepotidacin, the first oral antibiotic to offer a new mechanism of action in uncomplicated urinary ...

GSK is paying $66 million upfront to license ... Tebipenem is the first oral drug in the carbapenem antibiotic class to reach late-stage development and, despite the desperate need for new ...

PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI) is expected to be completed in Q2 ...

With Sunday’s Academy Awards ceremony in the rearview mirror, GSK is looking ahead to a potential blockbuster premiere of its own. The British Big Pharma has filed depemokimab for FDA approval ...

GSK (GSK) announced the US Food and Drug Administration, FDA, has accepted for review the Biologics License Application, BLA, for the use of depemokimab in two indications. The proposed ...